Metagenomi reports durable FVIII activity >16 mo in NHP hemophilia A study; MGX-001 IND on track for 2026

Metagenomi Therapeutics, Inc.

FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.
MGX-001 bioengineered FVIII showed higher activity vs wild-type at similar integration rates in separate NHP study.
No off-target editing identified to date in orthogonal assays; program targeting IND filing in 2026.
Transient liver transaminase elevation at AAV/LNP dosing; no safety findings on albumin or bilirubin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.